Cutia Therapeutics (CUTIA-B) saw its stock price surge 5.34% in pre-market trading on Friday, following the company's announcement of a significant share placing. The biopharmaceutical firm revealed plans to issue 28.9 million new shares at HK$8.40 per share, a move set to bolster its financial position.

According to the company's statement, the share placing represents approximately 9.05% of Cutia Therapeutics' current issued shares. After deducting related fees and expenses, the company expects to net approximately HK$240.26 million (about US$30.7 million) from this transaction. This substantial capital raise appears to have sparked investor enthusiasm, driving the stock's pre-market rally.

While the company has not specified the intended use of the proceeds, such capital raises are often viewed positively by the market, suggesting potential for growth, expansion, or investment in research and development. The strong investor response, as reflected in the stock's movement, may indicate confidence in Cutia Therapeutics' future prospects and its ability to effectively utilize the newly raised funds.